Clinical Trial Update: A Phase I-II Study of PAXG in Stage III-IV Pancreatic Adenocarcinoma [Phase 1, Phase 2]

View source ↗

Summary

A Phase I/II trial evaluating the investigational agent PAXG in patients with stage III–IV pancreatic adenocarcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Adenocarcinoma
• Pancreatic Cancer

Drugs mentioned

• PAXG

Snippet

Sponsor: IRCCS San Raffaele | Conditions: Pancreatic Cancer | Phase 1, Phase 2 | Status: COMPLETED